University Hospitals of Cleveland Medical Center
Welcome,         Profile    Billing    Logout  
 18 Trials 
54 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Miller, Karen K
NCT05354141: Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Recruiting
3
970
US
ExoFlo, Intravenous normal saline
Direct Biologics, LLC
Acute Respiratory Distress Syndrome, ARDS
03/25
08/25
NCT04779216: Effects of Romosozumab on Bone Density in Women with Anorexia Nervosa

Active, not recruiting
3
30
US
Romosozumab Prefilled Syringe, Placebo, Alendronate 70Mg Tab
Karen Klahr Miller, MD, Amgen
Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
10/24
10/25
NCT04833140: Estrogen Administration for the Treatment of NASH in Postmenopausal Women

Recruiting
3
60
US
Estradiol patch, Placebo
Massachusetts General Hospital
NASH - Nonalcoholic Steatohepatitis
05/27
05/27
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
KOURAGE, NCT06374797: A Study of Auxora in Patients with AKI and Injurious Lung "Crosstalk"

Recruiting
2
150
US
Auxora, Placebo
CalciMedica, Inc.
Acute Kidney Injury
08/25
08/25
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT04481919: Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

Recruiting
2
474
US
Protocolized diuretic therapy
Vanderbilt University Medical Center
Heart Failure, Acute Heart Failure
09/26
12/26
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
NCT05647213: Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Recruiting
1
50
US
iPSC-CL
HeartWorks, Inc.
Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
02/26
02/29
NCT02766920: Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

Not yet recruiting
N/A
10
US
CCD-1042
Massachusetts General Hospital
Major Depressive Disorder
08/18
 
NCT06588426: Clinical Readiness Skin Punch Biopsy Sample Collections

Recruiting
N/A
100
US
HeartWorks, Inc.
Congenital Heart Disease (CHD), Congenital Heart Defect
01/27
07/27
INDICATE-HF, NCT04886128: Improving Diagnostic Accuracy for Acute Heart Failure

Active, not recruiting
N/A
2800
US
Vanderbilt University Medical Center, Wayne State University
Acute Heart Failure, Dyspnea, Dyspnea; Cardiac
06/25
06/25
Strohl, Kingman
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
07/25
07/25
NCT06255613: Validation of Belun Ring Gen3 Deep Learning Algorithms With Subxiphoid Body Sensor

Recruiting
N/A
79
US
Belun Ring, Belun Cor
Belun Technology Company Limited, University Hospitals Cleveland Medical Center
Sleep-Disordered Breathing, Sleep Architecture, Arrhythmia
03/26
09/27
SUPRA, NCT04861038: Study Using Negative Pressure to Reduce Apnea

Active, not recruiting
N/A
900
US
aerSleep II
Sommetrics, Inc.
Sleep Apnea, Obstructive, Apnea, Sleep
12/25
12/25
CO-STAR, NCT05608486: Continuation Protocol for Study Using Negative Pressure to Reduce Apnea Trial

Available
N/A
NA
aerSleep II, Continuous Negative External Pressure (cNEP)
Sommetrics, Inc.
Obstructive Sleep Apnea, Sleep Apnea
 
 
Han, Jenny E
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
07/25
07/25
NCT06404047: RECOVER-ENERGIZE Platform Protocol

Recruiting
N/A
660
US
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Long COVID, Long Covid19, Long Covid-19
10/25
01/26
Kruse, Dawn
STOP360AG, NCT05548283: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Recruiting
4
730
Canada, US
Beta-lactam antibiotic, β-lactam, Aminoglycoside, AG
Chris Goss, University of Washington, Medical University of South Carolina, Cystic Fibrosis Foundation
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
11/26
11/26
NCT06159725: A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis

Recruiting
1/2
41
US
CMTX-101, Placebo
Clarametyx Biosciences, Inc.
Persistent Infection, Cystic Fibrosis
08/25
08/25
NCT06052293: Phase 1 Study to Assess Safety and Efficacy of ANG003

Completed
1
51
US
ANG003, Dose Level 1, Dose Level 2, Dose Level 3, and Dose Level 4.
Anagram Therapeutics, Inc.
Exocrine Pancreatic Insufficiency
07/24
07/24
CHEC-SC, NCT03350828: CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes

Active, not recruiting
N/A
5000
US
Nicole Hamblett, Cystic Fibrosis Foundation
Cystic Fibrosis
12/26
12/26
NICE-CF, NCT05362344: Colorectal Cancer Screening in Cystic Fibrosis

Active, not recruiting
N/A
350
US
Stool tests, Stool-based Fecal Immunochemical Testing (FIT) test and Stool-based DNA test (Cologuard) test.
University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation
Cystic Fibrosis, Colorectal Cancer, Adenoma
03/25
06/25
NCT06504589: A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Recruiting
N/A
400
US
Nicole Hamblett, Washington University School of Medicine, Florida State University, University of North Carolina, Chapel Hill, University of Toronto, Cystic Fibrosis Foundation
Cystic Fibrosis
08/29
08/29
STOP PEDS RCT, NCT06654752: Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Recruiting
N/A
430
Canada, US
Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
University of Washington, the Collaborative Health Studies Coordinating Center, Cystic Fibrosis Foundation
Cystic Fibrosis
12/27
02/29
BEGIN, NCT04509050: Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

Recruiting
N/A
210
US
Ivacaftor or elexacaftor/tezacaftor/ivacaftor, Kalydeco or Trikafta, Vertex (VX)-770 or VX-445/VX-661/VX-770
Sonya Heltshe, Cystic Fibrosis Foundation, University of Washington, University of Alabama at Birmingham
Cystic Fibrosis
12/29
12/29
MAYFLOWERS, NCT04828382: Prospective Study of Pregnancy in Women with Cystic Fibrosis

Active, not recruiting
N/A
285
US
Amalia Magaret, University of Texas, National Jewish Health, Cystic Fibrosis Foundation
Pregnancy Related, Cystic Fibrosis
12/26
12/26
Terrell, Eileen
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
SPARX3, NCT04284436: Study in Parkinson Disease of Exercise

Recruiting
N/A
370
Canada, US
Treadmill walking
Northwestern University, University of Pittsburgh, The Parkinson Study Group
Parkinson Disease
07/27
07/28
Godusevic, Lejla
STOP360AG, NCT05548283: Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Recruiting
4
730
Canada, US
Beta-lactam antibiotic, β-lactam, Aminoglycoside, AG
Chris Goss, University of Washington, Medical University of South Carolina, Cystic Fibrosis Foundation
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
11/26
11/26
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed
2
48
US
AP-PA02, Placebo
Armata Pharmaceuticals, Inc.
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
07/24
08/24
CARPO, NCT04681066: A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS

Completed
2
216
US, RoW
CM-4620 Injectable Emulsion or CM-4620-IE, Auxora, Placebo
CalciMedica, Inc.
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
05/24
05/24
NCT06504589: A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Recruiting
N/A
400
US
Nicole Hamblett, Washington University School of Medicine, Florida State University, University of North Carolina, Chapel Hill, University of Toronto, Cystic Fibrosis Foundation
Cystic Fibrosis
08/29
08/29
MAYFLOWERS, NCT04828382: Prospective Study of Pregnancy in Women with Cystic Fibrosis

Active, not recruiting
N/A
285
US
Amalia Magaret, University of Texas, National Jewish Health, Cystic Fibrosis Foundation
Pregnancy Related, Cystic Fibrosis
12/26
12/26
Howarter, April
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Cakulev, Ivan
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Connors, Barbara
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
Walker, Tiffany
NCT05946551: Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

Terminated
3
5
US
Cetirizine, Famotidine, HRA, Cetirizine Placebo, Famotidine Placebo
Emory University, CURE Drug Repurposing Collaboratory (CDRC)
COVID-19
06/24
06/24
RECOVER-AUTO, NCT06305780: NOMIC Platform Protocol

Recruiting
2
380
US
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Kanecia Obie Zimmerman
Long COVID, Long Covid19, Long Covid-19
12/25
03/26
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Active, not recruiting
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
07/25
07/25
Griggs, Stephanie
SLEEPT1D, NCT04975230: Self-Management in Young Adults With Type 1 Diabetes

Completed
N/A
44
US
Sleep Self-Management
Case Western Reserve University, National Institute of Nursing Research (NINR), National Institutes of Health (NIH)
Type 1 Diabetes
11/23
11/24
NCT05823142: Self-Management in Young Adults With Type 1 Diabetes 2023

Recruiting
N/A
248
US
CB Sleep
Case Western Reserve University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Type1diabetes
12/27
07/28
McKnight, Amy
DTU-STEMI, NCT03947619: Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: the STEMI-DTU Trial

Active, not recruiting
N/A
527
Europe, Canada, US
Impella CP® placement prior to reperfusion with Primary PCI
Abiomed Inc.
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
09/24
10/30
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
NCT06523166: Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics

Not yet recruiting
N/A
320
US
Transesophageal echocardiography (TEE), Cardiac CTA
University Hospitals Cleveland Medical Center, Boston Scientific Corporation
Device Related Thrombosis, Peri-device Leak
05/25
05/25
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Recruiting
N/A
100
US
LimFlow Stent Graft System
LimFlow, Inc.
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease
05/27
05/27
Guzman-Nguyen, Ayanna
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT03970343: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

Recruiting
N/A
620
US
OPTIMIZER Smart System
Impulse Dynamics
Heart Failure
03/26
03/26

Download Options